HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.